This research is something that will either matter quite a bit or not at all. Frankly, it’s premature at this point. A team at King’s College Hospital in London just published a case report describing a patient who developed acute psychosis five months after starting ruxolitinib. Before we go any further, we need to […]
Pevonedistat targets malignant cells in myeloproliferative neoplasms
Key Points Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells. Pevonedistat reduces disease burden in MPN mouse models. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Abstract Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone […]
BESREMi, Ropeginterferon FDA approved Treatment for PV
by David Wallace Patients are Asking – MPN Expert Dr. Ghaith Abu-Zeinah discusses Ropeginterferon (BESREMi), new Treatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi was recently approved by the FDA to treat polycythemia vera. Should I switch from Pegasys to the new FDA approved interferon? How might BESREMi change the treatment paradigm […]
New Horizons in MPN Treatment, A Review of Therapeutic Options
Abstract Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN patients have shortened survival […]
Myelofibrosis, New Markers of Disease Progression
Simple Summary Disease progression and prognosis in PMF are usually associated with worsening of anemia, increase of circulating blasts, and, more recently, with the presence, in addition to the “classical” driver mutations, of JAK2, MPL, and CALR genes, as well as of cytogenetic and molecular abnormalities that have been incorporated into new genetically based prognostic scoring systems. We have […]
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 44
- Next Page »
